Perineural Platelet-rich Plasma for Diabetic Neuropathy Pain
CompletedNot applicableNCT03601494
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Peripheral neuropathy is very common in diabetes mellitus (DM). Till now there is no available effective therapy for this pathology. Objective: To evaluate the clinical effect of perineural platelet-rich plasma (PRP) injection as a treatment of diabetic peripheral neuropathy (DPN).
Study details
- Official title
- Perineural Platelet Rich Plasma for Pain and Disability Management in Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- Other: perineural injection of platelet-rich plasma
- Drug: medical
- Sponsor
- Assiut University
- Start date
- 2017-02-01
- Primary completion
- 2017-11-22
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * type II diabetes mellitus * diabetic peripheral neuropathy * six months duration of symptoms, Exclusion Criteria: * other causes of neuropathy * patient refusal * ulcers or amputations * peripheral vascular diseases * vertebral spine disease * connective tissue disease * platelet dysfunction syndrome * critical thrombocytopenia * local infection * coagulopathy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03601494